Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Universal Ibogaine Inc ( (TSE:IBO) ) has provided an announcement.
Universal Ibogaine Inc. has provided a bi-weekly update on its continued delay in filing audited financial statements for the year ended July 31, 2025, and related disclosures, which has led to a management cease trade order requiring ongoing status reports under Canadian securities rules. The company says it remains in compliance with its disclosure obligations, expects no additional specified defaults, and plans to complete the audit once its restructuring progresses and any necessary exchange approvals are secured. As part of that restructuring, Universal Ibogaine has temporarily closed its Kelburn Recovery Centre near Winnipeg and is pursuing financing options that may include a sale of all or part of the property, with a letter of intent for a potential transaction under negotiation. Proceeds from a possible sale are intended to fund completion of the overdue audit and repay recently matured convertible debt, while allowing the company to refocus its resources on its core medical research business and its planned clinical trial application to Health Canada for ibogaine-based treatment of opioid use disorder.
More about Universal Ibogaine Inc
Universal Ibogaine Inc. is a Canadian life sciences company focused on transforming addiction treatment by developing medicalized ibogaine-based therapies. The company’s core strategy centers on a planned Canadian clinical trial targeting opioid use disorder, with the longer-term goal of commercializing its treatment protocols globally through future licensing agreements.
Average Trading Volume: 505,931
Technical Sentiment Signal: Sell
Current Market Cap: C$1.37M
Find detailed analytics on IBO stock on TipRanks’ Stock Analysis page.